Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Zhonghua Xin Xue Guan Bing Za Zhi|June 1, 2005
[China coronary secondary prevention study (CCSPS)]Zong-Liang Lu, Zhonghua Xin Xue Guan Bing Za Zhi|January 16, 2007
[The beneficial effects of lipid-lowering therapy with xuezhikang on cardiac events and total mortality in coronary heart disease patients with or without hypertension: a random, double-blinded, placebo controlled clinical trial]Bao-min DU, Zong-liang Lu, Zuo Chen, et al.Zhonghua Xin Xue Guan Bing Za Zhi|March 28, 2006
[China coronary secondary prevention study (CCSPS): outcomes from analysis of coronary heart disease patients with diabetes]Zong-liang Lu, Bao-min Du, Zuo Chen, et al.Zhonghua Nei Ke Za Zhi|April 21, 2006
[China coronary secondary prevention study: analysis of patients with different myocardial infarction history]Bao-min Du, Zong-liang Lu, Zuo Chen, et al.Journal of the American Geriatrics Society|July 5, 2007
Effect of xuezhikang on cardiovascular events and mortality in elderly patients with a history of myocardial infarction: a subgroup analysis of elderly subjects from the China Coronary Secondary Prevention StudyPing Ye, Zong-Liang Lu, Bao-min Du, et al.Journal of Clinical Pharmacology|July 16, 2009
Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS)Jian-Jun Li, Zong-Liang Lu, Wen-Rong Kou, et al.Annals of Medicine|March 31, 2010
Impact of Xuezhikang on coronary events in hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS)Jian-Jun Li, Zong-Liang Lu, Wen-Rong Kou, et al.Clinical and Experimental Hypertension (New York, N.Y. : 1993)|November 25, 2010
Long-term effects of Xuezhikang on blood pressure in hypertensive patients with previous myocardial infarction: data from the Chinese Coronary Secondary Prevention Study (CCSPS)Jian-Jun Li, Zong-Liang Lu, Wen-Rong Kou, et al.Oncology Reports|July 20, 2016
Platycodin D, a metabolite of Platycodin grandiflorum, inhibits highly metastatic MDA-MB-231 breast cancer growth in vitro and in vivo by targeting the MDM2 oncogeneYa Kong, Zong-Liang Lu, Jia-Jia Wang, et al.Journal of Cardiovascular Pharmacology|February 22, 2007
Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China coronary secondary prevention study (CCSPS)Shui-ping Zhao, Zong-liang Lu, Bao-min Du, et al.Pageof 2